Quality and Regulatory Requirements for Clinical-Grade iPSC Master Cell Banks

Induced pluripotent stem cells (iPSCs) have revolutionised regenerative medicine, providing a renewable and versatile source of cells for advanced therapies. Their ability to virtually differentiate into any adult human cell type makes them a powerful platform for next-generation allogeneic treatments. Allogeneic iPSC-derived products are now the preferred manufacturing model, requiring the establishment of clinical-grade master cell banks (MCBs) to ensure safety, consistency, and GMP compliance.

The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) are the primary authorities regulating these therapies. While both aim to ensure patient safety, their distinct frameworks influence clinical trial approval pathways and post-market monitoring.

Bridging innovation and regulation remains essential to translate iPSC-based therapies from discovery to the clinic.

The manufacturing process for iPSC-derived allogeneic therapies requires the establishment of MCBs.

MCBs provide a consistent, high-quality and stable source of cells. Leveraging automation and scalable manufacturing processes reduces costs and improves accessibility for patients in need.

The EU and US are shaping the regulatory path for iPSC-based therapies.

• Risk-based and adaptive approach, allowing earlier clinical entry and post-approval optimisation, with safety oversight continuing throughout the product lifecycle.
• iPSCs fall under the category of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) being regulated as biologics.

Both demand strict Good Manufacturing Practices (GMP) compliance.

Harmonisation efforts, such as the Parallel Scientific Advice (PSA) mechanism, aim to align global standards, allowing for joint consultations to streamline development, and ensuring global accessibility while maintaining safety and efficacy.

The EMA and the FDA outline the Qualification Requirements for iPSCs MCBs Manufacturing, including:

Stemmatters develops and implements procedures for the isolation and banking of a wide variety of human cells.

• GMP-certified manufacturer (registered at the EudraGMDP database) and manufacturing authorisation holder for cell therapy products.
• Manufacturing of research and/or clinical-grade MCBs and WCBs, filled aseptically in different primary containers, and stored under vapour phase liquid nitrogen.
• Development of manufacturing workflows supporting process scale-up, regulatory compliance and batch-to-batch consistency.
• QC testing of cell lines according to applicable guidelines, for characterisation of their identity, safety, purity, quality, and potency.
• Support for the review of CMC documentation  of cell-based medicinal products for regulatory submission.
• Supply of qualified cell starting material with full traceability of materials used and associated supporting documentation, including SOP’s and batch records.

Access the full scientific article through our Publications page.

PUBLICATIONS